PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs by Ataseven, Beyhan et al.
© 2014 Ataseven et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
OncoTargets and Therapy 2014:7 1723–1731
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1723
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S62676
PTK7 as a potential prognostic and predictive 
marker of response to adjuvant chemotherapy  










1Department of gynecology and 
gynecologic Oncology, Kliniken 
essen-Mitte, essen, germany; 
2Department of gynecology and 
Obstetrics, rotkreuzklinikum Munich, 
Munich, germany; 3Department 
of gynecology and Oncology, 
interdisciplinary Oncology center 
Munich, Munich, germany; 4Breast 
center, Department of gynecology 
and Obstetrics, ludwig-Maximilian-
University Munich, Munich, 
germany; 5Department of Pathology, 
rotkreuzklinikum Munich, Munich, 
germany; 6Department of Molecular 
Biology, Max-Planck-institute of 
Biochemistry, Martinsried, germany
correspondence: Beyhan ataseven 
Department of gynecology and 
gynecologic Oncology, Kliniken essen-
Mitte, evangelische huyssens-stiftung, 
henricistrasse 92, 45136 essen, germany 
Tel +49 201 174 34201 
Fax +49 201 174 34200 
email ataseven@gmx.net
Abstract: Biomarkers predicting resistance to particular chemotherapy regimens could play a 
key role in optimally individualized treatment concepts. PTK7 (protein tyrosine kinase 7) belongs 
to the receptor tyrosine kinase family involved in several physiological, but also malignant, cell 
behaviors. Recent studies in acute myeloid leukemia have associated PTK7 expression with 
resistance to anthracycline therapy. PTK7 mRNA expression in primary tumor tissue (PTT) and 
corresponding lymph node tissue (LNT) were retrospectively measured in 117 patients with early 
breast cancer; PTK7 expression was available in 103 PTT and 108 LNT samples. Median age was 
60 years (range, 27–87 years). At a median follow-up of 28.5 months, 6 deaths and 16 recurrences 
had occurred. PTK7 expression correlations with clinicopathological features were computed and 
PTK7 expression effects on patient outcome were analyzed in three cohorts defined by adjuvant 
treatment: anthracycline-based treatment, other chemotherapy regimens (including taxane or 
other substances), or no chemotherapy. Association of PTK7 expression with clinicopathological 
features was seen only for age in PTT and nodal stage in LNT. High LN PTK7 was associated 
with poorer disease-free survival (DFS) in the total population (3-year DFS: low [81.7%] ver-
sus high [70.4%]; P=0.016) and in patients without adjuvant chemotherapy (3-year DFS: low 
[91.7%] versus high [22.3%]; P,0.001), but not in patients receiving adjuvant chemotherapy 
(P=0.552). DFS stratified by PTK7 expression was compared in treatment cohorts: In patients 
with low LN PTK7 expression, neither chemotherapy cohort showed significantly better survival 
than the no-chemotherapy cohort. In patients with high LN PTK7 expression, those receiving 
chemotherapy, including substances other than anthracyclines, but not those receiving only 
anthracycline-based chemotherapy, showed significantly better DFS than those receiving no 
chemotherapy (P=0.001). Our results support earlier findings that PTK7 may be a prognostic 
and predictive marker associated with resistance to anthracycline-based chemotherapy. Further 
investigations are needed to validate these findings in breast cancer.
Keywords: breast cancer, PTK7, protein tyrosine kinase 7, chemoresistance, prognostic  factors, 
predictive factors
Introduction
Breast cancer (BC) is the most common malignancy for women in developed countries. 
During the last century, advances in screening, surgery, radiotherapy, and systemic 
therapy have led to high rates of local and distant disease control, resulting in survival 
improvement for patients with early-stage BC.1–3 So far, it is accepted that BC is a 
systemic disease, with micrometastatic involvement at diagnosis in many patients. 
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used to eradicate potential micrometastatic  disease in early 
treatment of BC patients. Adjuvant systemic therapies 
reduce risk for relapse and death, as shown in several meta-
analyses.4–6 In terms of targeted therapy, hormonal therapy 
in hormone receptor-positive7–9 and trastuzumab therapy in 
human epidermal growth factor receptor 2 (HER2)-posi-
tive10,11 patients are well established.  However, chemotherapy 
remains an important backbone in systemic treatment, 
especially in patients with high relapse risk. Anthracycline-
based poly-chemotherapy regimens are most widely used; 
the addition of taxanes into chemotherapy has improved 
survival benefits in the adjuvant setting.5 Unfortunately, dose 
limiting and long-term adverse effects, as well as resistance, 
represent challenges to further improvement in the efficacy 
of adjuvant BC chemotherapy.12 Therefore, it is very impor-
tant to understand the molecular mechanism of resistance to 
chemotherapeutic drugs and spare the nonnegligible adverse 
effects for patients.
Protein tyrosine kinase 7 (PTK7), also known as colon 
carcinoma kinase, is an evolutionary, highly conserved cell 
surface planar cell polarity (PCP) receptor that belongs to 
the family of receptor tyrosine kinase. The PTK7 gene is 
located on chromosome 6 (6p21.1–p12.2),13 and it encodes 
a transmembrane protein containing seven immunoglobulin-
like loops, a transmembrane domain, and an inactive catalytic 
tyrosine kinase domain.14,15 The ligand has not yet been 
identified. PTK7 has been shown to be highly involved in the 
canonical and noncanonical Wnt pathway.16 It plays a role in 
multiple cellular processes including tube formation,17 migra-
tion,18 and invasion of endothelial cells and angiogenesis.19 
It is believed that PTK7 may affect cell clustering or cell 
contact persistence. Increased expression of PTK7 has been 
found in several human tumors, suggesting a role in human 
carcinogenesis.20–25 However, the prognostic effect of PTK7 
expression in cancer remains unclear. In a previous study, 
we identified PTK7 as a potential mediator of motility and 
invasiveness of BC cells.26 A recent study indicates that 
PTK7 may induce resistance to anthracycline chemotherapy 
in human bone cancer cell lines and acute myeloid leukemia 
(AML) patients.24 However, the role of PTK7 in early BC 
in the development of acquired chemoresistance against 
chemotherapeutic agents, including anthracyclines, has not 
yet been elucidated.
The aim of our analysis was to investigate messenger 
RNA (mRNA) expression of PTK7 by reverse transcription-
polymerase chain reaction (RT-PCR) in early BC, to correlate 
PTK7 expression with clinicopathological features, to evalu-
ate the effect of PTK7 expression on outcome in primary BC 
patients, and to evaluate a possible predictive role of PTK7 
expression regarding chemotherapy.
Material and methods
Patients and tissue collection
From 2006 to 2010, 117 BC patients (median age at diag-
nosis, 60 years; range, 27–87 years; 88/117 [75.2%] with 
infiltrated LN and 29/117 [24.8%] with noninfiltrated LN) 
were included from the Red Cross Women’s Hospital Munich, 
Germany. This study was approved by Ethikkommission 
Ludwig-Maximilians-Universität ethics committee. Patients 
gave informed consent for the use of biological materials and 
relevant clinical data. Patients receiving neoadjuvant systemic 
therapy and those with primary distant metastases were 
excluded. Stage-adapted surgery was performed on breast 
and axillary LN. Primary tumor tissue (PTT) and lymph 
node tissue (LNT) were collected and stored immediately at 
−80°C from preparation. To ensure the histological status of 
harvested LN, the tissues were bisected, with half submitted 
for routine histology and the other half taken for examina-
tion by RT-PCR. Tumor grade; tumor, node, and metastasis 
classification; and histopathological tumor subtype were 
recorded. Hormonal receptor (estrogen receptor/progesterone 
receptor, immunoreactive score [IRS]) and HER2 status were 
assessed by immunohistochemistry and/or fluorescence in 
situ hybridization (all cases with HER2-HercepTest™ (Dako, 
Denmark) Score 2, according to American Society of Clinical 
Oncology/College of American Pathologists guidelines27). 
Patients were treated with radiotherapy according to current 
national guidelines. Clinicopathological features, type of 
chemotherapy, and follow-up were obtained from patient 
records.
Adjuvant systemic treatment was determined accord-
ing to guidelines at the time of diagnosis. Of 117 patients, 
69 (59%) received chemotherapy and 75 (64.1%) received 
hormonal therapy; 21 of 23 HER2-positive patients received 
combined chemotherapy/trastuzumab therapy; 45 patients 
did not receive chemotherapy because of patient preference, 
older age, or early disease stage. Typical chemotherapy 
regimens were either only anthracycline-based (doxorubicin/
cyclophosphamide [AC]/epirubicin/cyclophosphamide [EC]/
fluorouracil/doxorubicin/cyclophosphamide [FAC]/fluorou-
racil/epirubicin/cyclophosphamide [FEC], four to six cycles) 
or taxane-based (docetaxel/doxorubicin/cyclophosphamide 
[TAC]/fluorouracil/epirubicin/cyclophosphamide - docetaxel 
[FEC-Doc]/fluorouracil/epirubicin/cyclophosphamide - 
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relevance of PTK7 expression in breast cancer
Total rna isolation
Total RNA was isolated using the acid guanidine thiocyanate-
phenol-chloroform extraction method.28 After Na-acetate treat-
ment, the total RNA was extracted with phenol- chloroform, 
precipitated with isopropanol, resuspended with lysis buffer, 
reprecipitated with isopropanol, washed with 80% ethanol, 
and finally dissolved in diethyl pyrocarbonate-treated H
2
O. 
The total RNA concentration was determined by absorbance 
measurement (260/280 nm), and the quality of total RNA was 
verified by 1% agarose gel electrophoresis. Only samples with 
no evidence of DNA contamination and RNA degradation 
were used for cDNA synthesis.
cDna synthesis
cDNA synthesis was performed using 5 µg total RNA in 
an oligo (desoxythymidine) primer mix (MWG Biotech, 
 Ebersberg, Germany; total volume, 10 µL), which was heated 
at 70°C for 3 minutes and then cooled on ice. A master mix 
containing 1× reverse transcriptase buffer, 1 mmol/L deoxy-
nucleotide triphosphates, 10 mmol/L dithiothreitol (DTT), 
40 U RNase inhibitor (40 U/µL; Fermentas), and 50 U avian 
myeloblastosis virus reverse transcriptase (25 U/µL; Molecular 
Diagnostics, Roche) was added and subsequently incubated at 
42°C for 2 hours. A stop reaction was performed with 80 µL 
Tris-ethylenediaminetetraacetic acid 10/0.1, followed by heat-
ing at 72°C for 7 minutes. The quality of the cDNA was verified 
using 1.5% agarose gel electrophoresis. Afterward, the cDNA 
probe was denatured with 10 µL and 1 N NaOH, pH neutralized 
with 5 µL 2 N HCl and 5 µL 2N Tris-HCl (pH, 7.5), and puri-
fied using the QIAquick PCR Purification kit (Quiagen, Hilden, 
Germany) according to the manufacturer’s instructions.
rT-Pcr
The PCR method was used to determine mRNA expres-
sion levels of PTK7 and α-tubulin (housekeeping gene) in 
fresh-frozen PTT and LNT samples. The following primer 
sequences were applied: PTK7-ex 7fwd, 5′-GGA AGC CAC 
ACT TCA CCT AGC AG-3′, PTK7-ex11rev, 5′-CTG CCA 
CAG TGA GCT GGA CAT GG-3′, α-TUB fwd, 5′-AAG 
TGA CAA GAC CAT TGG GGG AGG-3′, α-TUB rev, 5′ 
GGG CAT AGT TAT TGG CAG CAT-3′. All primers were 
synthesized by MWG Biotech. PCR was performed using 
1 µL cDNA as a template in a master mix containing 1× PCR 
buffer, 1 mmol/L deoxynucleotide triphosphates, 1 pmol/
µL of each specific primer, and 2.5 U Taq DNA polymerase 
(Sigma, Taufkirchen, Germany) for each sample and carried 
out in a thermal cycler (Eppendorf AG, Wessling-Berzdorf, 
Germany). PCR cycling conditions began with an initial DNA 
denaturation step at 94°C for 2 minutes, followed by 32 cycles 
with denaturation at 94°C for 30 seconds, primer annealing 
at the appropriate annealing temperature for 30 seconds, and 
extension at 72°C for 1  minute, followed by a final exten-
sion step at 72°C for 5 minutes. The amplified PCR products 
were analyzed by separation in a 2% agarose gel at 80 V for 
30 minutes. The mRNA expression of the PCR products, 
with a size of approximately 100 bp to 1 kbp, was evaluated 
semiquantitatively, using Aida Image Software (Raytest, 
Straubenhardt, Germany).
statistical analysis
Two-sample t-tests, one-way analysis of variance, or the 
Mann–Whitney U test were performed to test for associations 
between continuous and grouped variables; chi-square tests 
or Fisher’s exact test were performed to evaluate associations 
between grouped variables.
Disease-free survival (DFS) and overall survival (OS) 
were defined in months from time of surgery. DFS end points 
were recurrent tumor and distant metastasis or death from 
BC. Survival estimates were obtained by the Kaplan–Meier 
method; the log-rank test was used to analyze for group 
differences. A binary PTK7 expression variable (high versus 
low) was defined using median expression as a cutoff. All 
reported P-values are two-tailed, with a nominal significance 
level of 5%. Statistical analysis was performed using SPSS 
(version 20, IBM Corporation, New York, NY, USA).
Results
Patient characteristics and outcome
PTK7 mRNA expression in PTT and corresponding LNT were 
retrospectively measured in 117 early BC patients. Median age 
at diagnosis was 60 years (range, 27–87 years). At a median 
follow-up period of 28.5 months, there were 16 recurrences 
(13 distant, 3 local) and 6 deaths. For analysis, we defined 
cohort A as patients receiving exclusively anthracycline-based 
chemotherapy, cohort B as those receiving chemotherapy 
including agents other than anthracyclines (eg, taxane-based 
and others), and cohort C as patients receiving no chemo-
therapy. Table 1 describes and compares key parameters by 
cohort: Patients receiving no chemotherapy (cohort C) were 
older (median age, 72 years) than in cohorts A and B (60 and 
49 years, respectively). Significant differences among the 
three cohorts occurred in nodal status, histological type, and 
HER2 status. Neither in paired comparisons among the three 
treatment cohorts nor in comparisons of chemotherapy versus 
no chemotherapy (P=0.340; Figure 1A) were significant dif-
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PTK7 expression and association  
with clinicopathological features
PTK7 expression in PTT was distributed as follows: 1.72 (25th 
percentile), 3.04 (median), and 4.39 (75th percentile). PTK7 
expression in LNT was distributed as follows: 0.58 (25th 
percentile), 1.68 (median), and 3.15 (75th percentile).
A moderate correlation of PTK7 levels in PTT and 
LNT was seen (Spearman-Rho, 0.432; P,0.001). The fol-
lowing associations of PTK7 expression in PTT and LNT 
with clinicopathological features (age; grade; tumor, node, 
and metastasis category; steroid hormonal receptor; and 
HER2 status) were seen (Table 2). High PTK7 expression 
in PTT occurred more frequently in younger patients; high 
PTK7 expression in LNT was significantly associated with 
higher pathologic nodal status. As a rough measure of asso-
ciation, LNT PTK7 level (but not PTT PTK7 level) treated 
as a continuous variable was correlated with nodal status 
(Spearman-Rho, 0.537; P,0.001).
Prognostic effect of PTK7 expression
The effects of PTK7 expression in PTT and in LNT on DFS 
and OS were first analyzed for the collective as a whole. 
Although PTT PTK7 expression had no significant prognostic 
effect on DFS or OS, patients with low PTK7 expression in 
LNT had significantly better DFS than those with high PTK7 
(P=0.016; 3-year DFS: low versus high, 81.7% versus 70.4%). 
In univariate Cox regression, high LNT PTK7 expression was 
associated with a hazard ratio of 3.76 (95% CI: 1.19 - 11.9). 
LNT PTK7 expression had no significant effect on OS.
PTK7 expression and chemotherapy 
benefit prediction
In view of the prognostic effect of PTK7 expression in LNT, 
but not PTT, we consider LNT PTK7 expression in the fol-
lowing predictive analysis.
The effect of PTK7 expression on DFS differed accord-
ing to whether chemotherapy was administered at all. As 
illustrated in Figure 1B, patients in cohort C with high LNT 
PTK7 expression (n=14) showed significantly poorer DFS 
than those with low expression (n=21; 3-year DFS: 22.3% 
versus 91.7%; P.0.001); a corresponding difference was 
not seen in patients with chemotherapy (Figure 1C). These 
findings suggest a particular benefit from chemotherapy for 
patients with high LNT PTK7 expression.
Table 1 comparing cohorts a through c
Cohort A, exclusively  
anthracycline-based  
(n=19)
Cohort B,  
taxane-based/ 
others (n=50)






Median age in years, range 60 (44–73) 49 (27–75) 72 (36–87) ,0.001
size, pT (tumor stage) 0.241
 pT1 7 (36.8%) 17 (34.0%) 16 (35.5%)
 pT2 9 (47.4%) 28 (56.0%) 20 (44.4%)
 pT3 2 (20.0%) 5 (10.0%) 3 (6.7%)
 pT4 1 (14.3%) 0 (0%) 6 (13.3%)
histological type 0.017
 invasive ductal 16 (84.2%) 45 (90.0%) 32 (71.1%)
 invasive lobular 3 (15.8%) 1 (2.0%) 11 (24.4%)
 Other 2 (4.4%) 4 (8.0%) 2 (33.3%)
Pathologic nodal status (pn) 0.001
 pn0 2 (42.2%) 8 (16.0%) 19 (42.2%)
 pn1 6 (13.3%) 27 (54.0%) 6 (13.3%)
 pn2 11 (24.4%) 10 (20.0%) 11 (24.4%)
 pn3 9 (20.0%) 5 (10.0%) 9 (20.0%)
Pathologic grade 0.619
 g1 0 (0%) 4 (8.0%) 5 (11.1%)
 g2 11 (57.9%) 30 (60.0%) 26 (57.8%)
 g3 8 (42.1%) 16 (32.0%) 14 (31.1%)
estrogen receptor status 0.245
 estrogen receptor positive 13 (68.4%) 36 (72.0%) 38 (84.4%)
 estrogen receptor negative 6 (31.6%) 14 (28.0%) 7 (15.6%)
human epidermal growth factor receptor 2 status ,0.001
 human epidermal growth factor receptor 2 negative 18 (94.7%) 30 (61.2%) 41 (93.2%)
 human epidermal growth factor receptor 2 positive 1 (5.3%) 19 (38.8%) 3 (6.8%)
Notes: cohort a, patients receiving exclusively anthracycline-based chemotherapy. cohort B, patients receiving chemotherapy including agents other than anthracyclines 
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relevance of PTK7 expression in breast cancer
Taking into account the statistical power available, the 
hypothesis of an association of PTK7 with anthracycline 
resistance was investigated by evaluating the effect of PTK7 
expression on DFS in the treatment cohorts defined earlier. 
For patients with low LNT PTK7 expression, DFS differ-
ences in A versus C and in B versus C were not significant 
(Figure 2A and B). In patients with high PTK7 expression, 
the difference between cohort A and cohort C was borderline 
significant (P=0.060; Figure 2C), whereas a significant 
difference between cohorts B and C was observed (3-year 
DFS: 95.2% versus 20.8%; P=0.001; Figure 2D).
Chemotherapy selection could have been affected by dif-
ferences in clinicopathological variables (Table 1; eg, more 
high-risk patients in cohort B). However, in multivariate 
analysis, hormone receptor status or histological type did not 
enter the models, so the large difference between cohorts B 
and C persisted in high-PTK7 patients.
Discussion
The current study of patients with primary BC is the first to 
investigate associations of PTK7 mRNA expression in both 
PTT and axillary LNT with clinicopathological parameters, 
as well as the effect of PTK7 mRNA expression on survival 
according to adjuvant chemotherapy subcohorts.
PTK7 is thought to play an important role in migration, 
invasion, angiogenesis, cell proliferation, and cell apop-
tosis.19,29 In previous work, we showed that PTK7 is able 
to transform NIH3T3 cells and is a potential mediator of 
motility and invasiveness of BC cells.26 Furthermore, we 
demonstrated that inhibition of endogenous PTK7 signaling 
in highly invasive BC cells by a dominant negative mutation 
or by siRNA silencing results in loss of capacity to invade 
the surrounding matrix and to migrate into the wound area. 
Our clinical data are consistent with this biological role, sug-
gesting that the more PTK7 is expressed, the more aggressive 
the tumor cells are and the more they tend to migrate to the 
next destination (from PTT to LNT and from LNT to distant 
metastasis). PTK7 is upregulated in many human cancers 
(eg, lung cancer,20 gastric cancer,22 colon cancer,23,25 AML,24 
and liposarcoma21); however, the prognostic significance of 
higher PTK7 expression may depend on cancer entity. In gas-
tric cancer, for example, higher PTK7 expression has been 
linked to improved survival, whereas AML or liposarcoma 
patients with high tumor PTK7 had poorer outcomes.
This study detected a significant positive correlation 
between PTK7 expression in PTT and LNT, as well as a posi-
tive correlation between PTK7 expression level and nodal 
involvement (ie, tumor load). High LNT PTK7 expression 
was associated with substantially poorer DFS in the whole 
collective, with a hazard ratio of 3.76.
PTK7 expression is thought to be associated with resis-
tance to anthracycline chemotherapy.24 To investigate this 
question, our study has focused on survival, taking LNT 
PTK7 status and type of chemotherapy into account. PTK7 
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Figure 1 Kaplan–Meier curves for disease-free survival (DFs). (A) DFs in patients 
with and without adjuvant chemotherapy. (B) DFs in patients without adjuvant 
chemotherapy based on PTK7 expression. (C) DFs in patients with adjuvant 
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patients receiving no chemotherapy, but not in those receiving 
chemotherapy.
In our collective, high LNT PTK7 expression was 
associated with a significantly poorer DFS in patients 
receiving no chemotherapy, but not in those receiving 
chemotherapy.
In patients with high LNT PTK7 expression (but not in 
those with low LNT PTK7 expression), DFS in cohort A 
(anthracyclines only) was not significantly better than in the 
no-chemotherapy cohort (C) but was much better in cohort 
B (chemotherapy not limited to anthracyclines) than in 
cohort C. Taken together, these results are consistent with 
previous findings in AML, suggesting an association between 
high PTK7 and anthracycline resistance and with the inter-
pretation that chemotherapy regimens including agents other 
than anthracyclines are particularly effective in high-PTK7 
patients. In a recent article,30 we evaluated the effect of PTK7 
expression measured by immunohistochemistry in triple-
negative BC and observed a (nonsignificant) trend toward 
poorer survival of patients with PTK7-positive tumors treated 
with anthracycline-based chemotherapy (ie, consistent with 
the hypothesis of drug resistance).
To date, little progress has been made in the field of 
predictive biomarkers for chemotherapy benefit in BC. As a 
consequence, a vast majority of patients considered to be at 
moderate or high risk for relapse are treated with those cyto-
toxic agents viewed as the most active; namely, anthracyclines 
and taxanes, both of which are associated with significant 
adverse effects. Unfortunately, resistance remains a signifi-
cant drawback to clinical success in chemotherapy, as in other 
Table 2 clinical parameters of patients with primary breast cancer tissue (PTT) and lymph node tissue (lnT) displaying low or high 
PTK7 expression (binary variable)
PTK7 expression in PTT PTK7 expression in LNT
Total Low High P-value Total Low High P-value
age, years 1.000
  #50 40 17 (42.5%) 23 (57.5%) 40 20 (50.0%) 20 (50.0%)
  .50 77 49 (63.6%) 28 (36.4%) 0.033 68 34 (50.0%) 34 (50.0%)
Tumor size 0.640
  pT1 40 21 (52.5%) 19 (47.5%) 36 21 (58.3%) 15 (41.7%)
  pT2 59 34 (57.6%) 25 (42.4%) 56 26 (46.4%) 30 (53.6%)
  pT3 11 7 (63.6%) 4 (36.4%) 10 4 (40.0%) 6 (60.00%)
  pT4 7 4 (57.1%) 3 (42.9%) 0.915 6 3 (50.0%) 3 (50.0%)
histological type 0.360
  invasive ductal 96 51 (53.1%) 45 (46.9%) 90 44 (48.9%) 46 (51.1%)
  invasive lobular 15 11 (73.3%) 4 (26.7%) 12 8 (66.7%) 4 (33.3%)
  Other 6 4 (66.7%) 2 (33.3%) 0.297 6 2 (33.3%) 4 (66.7%)
lymph node status ,0.001
  n0 29 18 (62.1%) 11 (37.9%) 28 20 (71.4%) 8 (28.6%)
  n1 44 23 (52.3%) 21 (47.7%) 41 25 (61.0%) 16 (39.0%)
  n2 27 14 (51.9%) 13 (48.1%) 23 8 (34.8%) 15 (65.2%)
  n3 17 11 (64.7%) 6 (35.3%) 0.708 16 1 (6.2%) 15 (93.8%)
estrogen receptor status 0.067
  Positive 90 52 (57.8%) 38 (42.2%) 83 46 (55.4%) 37 (44.6%)
  negative 27 14 (51.9%) 13 (48.1%) 0.660 25 8 (32.0%) 17 (68.0%)
human epidermal growth  
factor receptor 2
0.058
  negative 92 56 (60.9%) 36 (39.1%) 83 46 (55.4%) 37 (44.6%)
  Positive 23 10 (43.5%) 13 (56.5%) 0.160 23 7 (30.4%) 16 (69.6%)
histological grading 0.479
  g1 9 5 (55.6%) 4 (44.4%) 9 6 (66.7%) 3 (33.3%)
  g2 70 41 (58.6%) 29 (41.4%) 65 33 (50.8%) 32 (49.2%)
  g3 38 20 (52.6%) 18 (47.4%) 0.837 34 15 (44.1%) 19 (55.9%)
chemotherapy type 0.348
  cohort a 19 12 (63.2%) 7 (36.8%) 17 6 (35.3%) 11 (64.7%)
  cohort B 50 25 (50.5%) 25 (50.0%) 50 25 (50.0%) 25 (50.0%)
  cohort c 45 26 (57.8%) 19 (36.8%) 0.561 39 22 (56.4%) 17 (43.6%)
Notes: cohort a: patients receiving exclusively anthracycline-based chemotherapy. cohort B: patients receiving chemotherapy, including agents other than anthracyclines 
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relevance of PTK7 expression in breast cancer
systemic therapy concepts. Therefore, identification of new 
markers with a predictive value regarding chemotherapy 
response can play a key role in the development of individu-
alized treatment strategies to further improve efficacy and 
minimize adverse effects.
Conclusive recommendations from the current study 
are not yet possible because of weaknesses such as a non-
standardized detection assay, retrospective trial design, 
nonrandomized treatment groups, and limited sample size. 
In particular, the results should not be interpreted as a recom-
mendation on which patients should receive adjuvant che-
motherapy or a particular kind of chemotherapy. However, 
the results are certainly hypothesis-generating and warrant 
validation in a larger BC collective, particularly in view of the 
independent biological and medical evidence for a predictive 
role of PTK7 in chemotherapy response, and particularly in 
anthracycline resistance.
Conclusion
To the best of our knowledge, this is the first report using 
RT-PCR for investigating the relationship between PTK7 
expression and outcome in BC specifically looking at 
anthracycline-based chemotherapy. High PTK7 expression 
in LNT is associated with high tumor load and with poorer 
DFS in patients with no chemotherapy or only-anthracycline-
based adjuvant chemotherapy, but not in patients treated by 
taxane-based chemotherapy. Provided these findings can 
be independently validated, PTK7 may be an important 
prognostic and predictive biomarker. Further strategies for 
targeting PTK7 may thus offer novel therapeutic opportuni-
ties in BC treatments.
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Figure 2 Kaplan–Meier curves for disease-free survival (DFs) distributed in therapy cohorts and protein tyrosine kinase (PTK) expression. (A) DFs in patients with low PTK7 
expression treated with only anthracycline-based chemotherapy (cohort a) versus no chemotherapy (cohort c). (B) DFs in patients with high PTK7 expression treated with 
only anthracycline-based chemotherapy (cohort a) versus no chemotherapy (cohort c). (C) DFs in patients with low PTK7 expression treated with taxane-based/other 
chemotherapy (cohort B) versus no chemotherapy (cohort c). (D) DFs in patients with high PTK7 expression treated with taxane-based/other chemotherapy (cohort B) 




















































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





support of Tatiana Knyazeva and Silvia Gärtner. The work 
was funded by the Max Planck Society. Statistical analysis 
(REK) was supported by a grant from the University of 
Munich (to NH).
Author contributions
BA provided the concept and design; recruited patients and 
collected tissue; provided experimental and data analysis and 
interpretation, critical revision, and final approval; and wrote 
the first draft of the manuscript and provided comments. AG 
provided experimental and data analysis and interpretation, 
critical revision, and final approval and reviewed the draft and 
provided comments. WE provided the concept and design, 
recruited patients and collected tissue, and performed experi-
mental and data analysis and interpretation, as well as critical 
revision, and provided comments. REK provided statistical 
analysis, data analysis and interpretation, critical revision, and 
review and comments on manuscript development, as well as 
final approval. BH provided experimental and data analysis and 
interpretation, critical revision, reviewed the draft, and provided 
comments. PK provided concept and design, experimental 
and data analysis and interpretation, critical revision, and final 
approval and reviewed the draft and provided comments. AU 
provided experimental and data analysis and interpretation, 
critical revision and final approval and reviewed the draft and 
provided comments. NH provided data analysis and interpreta-
tion and critical revision, reviewed and provided comments on 
manuscript development, and provided final approval.
Disclosure
PK and AU are listed as inventors on the European Patent 
Application no 10075169.2, “PTK-7 Protein Involved in 
Breast Cancer.” The other authors report no conflicts of 
interest in this work.
References
1. Peto R, Davies C, Godwin J, et al; Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG). Comparisons between different 
 polychemotherapy regimens for early breast cancer: meta-analyses of 
long-term outcome among 100,000 women in 123 randomised trials. 
Lancet. 2012;379(9814):432–444.
2. Darby S, McGale P, Correa C, et al; Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG). Effect of radiotherapy after breast-
conserving surgery on 10-year recurrence and 15-year breast cancer 
death: meta-analysis of individual patient data for 10,801 women in 17 
randomised trials. Lancet. 2011;378(9804):1707–1716.
3. Davies C, Godwin J, Gray R, et al; Early Breast Cancer Trialists’ 
 Collaborative Group (EBCTCG). Relevance of breast cancer hormone 
receptors and other factors to the efficacy of adjuvant tamoxifen: patient-
level meta-analysis of randomised trials. Lancet. 2011;378(9793): 
771–784.
 4. Ginés J, Sabater E, Martorell C, Grau M, Monroy M, Casado MA. 
Efficacy of taxanes as adjuvant treatment of breast cancer: a review 
and meta-analysis of randomised clinical trials. Clin Transl Oncol. 
2011;13(7):485–498.
 5. Palmieri C, Jones A. The 2011 EBCTCG polychemotherapy overview. 
Lancet. 2012;379(9814):390–392.
 6. Qin Y-Y, Li H, Guo X-J, et al. Adjuvant chemotherapy, with or without 
taxanes, in early or operable breast cancer: a meta-analysis of 19 ran-
domized trials with 30698 patients. PLoS ONE. 2011;6(11):e26946.
 7. Cuzick J, Sestak I, Baum M, et al; ATAC/LATTE investigators. Effect 
of anastrozole and tamoxifen as adjuvant treatment for early-stage breast 
cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12): 
1135–1141.
 8. Regan MM, Neven P, Giobbie-Hurder A, et al; BIG 1-98 Collaborative 
Group; International Breast Cancer Study Group (IBCSG). Assessment 
of letrozole and tamoxifen alone and in sequence for postmenopausal 
women with steroid hormone receptor-positive breast cancer: the BIG 
1–98 randomised clinical trial at 8⋅1 years median follow-up. Lancet 
Oncol. 2011;12(12):1101–1108.
 9. Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; 
International Breast Cancer Study Group and BIG 1-98 Collaborative 
Group. Interpreting Breast International Group (BIG) 1–98: a random-
ized, double-blind, phase III trial comparing letrozole and tamoxifen 
as adjuvant endocrine therapy for postmenopausal women with 
hormone receptor-positive, early breast cancer. Breast Cancer Res. 
2011;13(3):209.
 10. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of tras-
tuzumab plus adjuvant chemotherapy for operable human epidermal 
growth factor receptor 2-positive breast cancer: joint analysis of data 
from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25): 
3366–3373.
 11. Slamon D, Eiermann W, Robert N, et al; Breast Cancer International 
Research Group. Adjuvant trastuzumab in HER2-positive breast  cancer. 
N Engl J Med. 2011;365(14):1273–1283.
 12. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview 
of resistance to systemic therapy in patients with breast cancer. Adv Exp 
Med Biol. 2007;608:1–22.
 13. Banga SS, Ozer HL, Park SK, Lee ST. Assignment of PTK7 encoding 
a receptor protein tyrosine kinase-like molecule to human chromosome 
6p21.1–.p12.2 by fluorescence in situ hybridization. Cytogenet Cell 
Genet. 1997;76(1–2):43–44.
 14. Jung JW, Ji AR, Lee J, Kim UJ, Lee ST. Organization of the human 
PTK7 gene encoding a receptor protein tyrosine kinase-like mol-
ecule and alternative splicing of its mRNA. Biochim Biophys Acta. 
2002;1579(2–3):153–163.
 15. Park SK, Lee HS, Lee ST. Characterization of the human full-length 
PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule 
closely related to chick KLG. J Biochem. 1996;119(2):235–239.
 16. Lhoumeau AC, Puppo F, Prébet T, Kodjabachian L, Borg JP. PTK7: 
a cell polarity receptor with multiple facets. Cell Cycle. 2011;10(8): 
1233–1236.
 17. Lu X, Borchers AG, Jolicoeur C, Rayburn H, Baker JC, Tessier-
Lavigne M. PTK7/CCK-4 is a novel regulator of planar cell polarity in 
 vertebrates. Nature. 2004;430(6995):93–98.
 18. Peradziryi H, Tolwinski NS, Borchers A. The many roles of PTK7: 
a versatile regulator of cell-cell communication. Arch Biochem Biophys. 
2012;524(1):71–76.
 19. Shin WS, Maeng YS, Jung JW, Min JK, Kwon YG, Lee ST. Soluble 
PTK7 inhibits tube formation, migration, and invasion of endothelial 
cells and angiogenesis. Biochem Biophys Res Commun. 2008;371(4): 
793–798.
 20. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary 
adenocarcinoma by expression profiling of eight genes as determined by 
quantitative real-time reverse transcriptase polymerase chain reaction. 






























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open access 
journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.





relevance of PTK7 expression in breast cancer
 21. Gobble RM, Qin LX, Brill ER, et al. Expression prof iling of 
liposarcoma yields a multigene predictor of patient outcome and 
identifies genes that contribute to liposarcomagenesis. Cancer Res. 
2011;71(7): 2697–2705.
 22. Lin Y, Zhang LH, Wang XH, et al. PTK7 as a novel marker for favorable 
gastric cancer patient survival. J Surg Oncol. 2012;106(7):880–886.
 23. Mossie K, Jallal B, Alves F, Sures I, Plowman GD, Ullrich A. Colon 
carcinoma kinase-4 defines a new subclass of the receptor tyrosine 
kinase family. Oncogene. 1995;11(10):2179–2184.
 24. Prebet T, Lhoumeau AC, Arnoulet C, et al. The cell polarity PTK7 
receptor acts as a modulator of the chemotherapeutic response 
in acute myeloid leukemia and impairs clinical outcome. Blood. 
2010;116(13):2315–2323.
 25. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated 
with metastasis of colorectal cancer. Science. 2001;294(5545): 
1343–1346.
 26. Gärtner S, Gunesch A, Knyazeva T, et al. PTK 7 is a transforming 
gene and prognostic marker for breast cancer and nodal metastasis 
 involvement. PLoS ONE. 2014;9(1):e84472.
 27. Wolff AC, Hammond ME, Schwartz JN, et al; American Society of 
Clinical Oncology; College of American Pathologists. American Society 
of Clinical Oncology/College of American Pathologists guideline 
recommendations for human epidermal growth factor receptor 2 testing 
in breast cancer. J Clin Oncol. 2007;25(1):118–145.
 28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 
1987;162(1):156–159.
 29. Meng L, Sefah K, O’Donoghue MB, et al. Silencing of PTK7 in 
colon cancer cells: caspase-10-dependent apoptosis via mitochondrial 
 pathway. PLoS ONE. 2010;5(11):e14018.
 30. Ataseven B, Angerer R, Kates R, et al. PTK7 expression in triple-






























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
